Workflow
Healthcare
icon
Search documents
X @Bloomberg
Bloomberg· 2025-08-29 08:24
Industry Partnership - Eli Lilly is partnering with Chinese online healthcare platform JD Health [1] Market Expansion - The partnership aims to sell Eli Lilly's blockbuster drugs for obesity and diabetes online in China [1]
X @Investopedia
Investopedia· 2025-08-28 22:30
Here are the latest moves in Warren Buffett's Berkshire Hathaway portfolio, including his new bets on Lennar (LEN), D.R. Horton (DHI), Nucor (NUE), and, most notably, UnitedHealth Group (UNH). https://t.co/c8nwjlEfnR ...
HIMS & HERS ALERT: Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2025-08-27 20:36
Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Hims & Hers Health, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [1][2]. Group 1: Legal Investigation - The law firm is representing long-term stockholders of Hims & Hers who held shares between April 29, 2025, and June 23, 2025, and is encouraging them to discuss their legal rights [1][3]. - A class action complaint was filed on June 25, 2025, concerning the alleged misleading statements and omissions made by the company during the class period [1][2]. Group 2: Allegations Against Hims & Hers - The lawsuit claims that Hims & Hers made false statements regarding its collaboration with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for its subscribers [2]. - Specific allegations include that Hims & Hers misrepresented the approval of its compounded semaglutide products and the partnership with Novo, which purportedly misled investors and led to a significant decline in the company's stock value [2].
Bio-Techne to Present at Upcoming Investor Conferences
Prnewswire· 2025-08-27 11:00
Company Overview - Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [2] - The company generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide [2] Upcoming Investor Conferences - Bio-Techne will present at the following investor conferences: - 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 10:15 AM EDT [1] - Baird 2025 Global Healthcare Conference on September 9, 2025, at 9:05 AM EDT [1] - Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025, at 10:45 AM EDT [1] - A live webcast of the presentations will be available on the company's Investor Relations website [1]
Choose hope, overcome fear, defeat cancer | Dr. Wasim Phoplunkar | TEDxMaharashtra College
TEDx Talks· 2025-08-26 15:29
#tedxmaharashtracollege #MaharashtraCollege #DrwasimPhoplunkar #oncologist Dr. Wasim S. Phoplunkar is a globally acclaimed Radiation Oncologist , with 25+ years of global experience across India, Canada and Saudi Arabia. From cutting-edge treatments like IMRT, IGRT & RapidArc to humanizing the cancer care journey, Dr. Phoplunkar is redefining healing with both technology and compassion This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn ...
X @Forbes
Forbes· 2025-08-26 07:10
Medallion is setting up a national clearinghouse to streamline a healthcare credentialing process that costs more than $1 billion annually. https://t.co/sC9zEPeyZF https://t.co/AUTUgNz0Cv ...
How AI adoption will impact the workplace. Morgan Stanley's Stephen Byrd breaks it down
CNBC Television· 2025-08-25 18:22
AI Impact on Economy - 摩根士丹利预测,随着人工智能的持续应用,标普500指数的市值可能增加高达 16 万亿美元[1] - 相对于公司收入而言,较低技术行业将成为人工智能的最大相对受益者,例如消费服务、资本货物和制造业相关行业[3][4] - 充分应用人工智能后,部分行业公司税前利润的增长可能超过 50%[4] - 美国工厂中机器人的完全成本可能在每小时 5 美元左右,远低于美国工厂工人的平均工资[6] - 在美国工厂中,机器人渗透率达到约 20% 的水平时,在美国生产的产品的登陆成本将与在中国制造并运往美国的产品相同[8] AI Application & Development - 微软展示了其最新的人工智能工具,该工具能够以远低于人类医生的成本,更准确地诊断患者[12] - 具有大量服务和物流的业务将从人工智能中受益,例如消费导向型行业和医疗保健行业[12] - 软件和编码以及法律行业的文件起草等领域将看到更多代理型人工智能的应用[10] Power Sector - 电力行业是释放数据中心所需电力,成为人工智能发展的关键[13]
FAITH AND LIFE | Jeyanth Venkatraman | TEDxYouth@RJM
TEDx Talks· 2025-08-25 16:51
Hello. In the pursuits of our goals, we often begin from nothing or closer to nothing. But what if I tell you we could kickstart from the halfway mark.Yes, believe you can. You are halfway there. When I say belief, when I say faith, it is the light that makes our life bright even during the darkest times.We all walk through life with questions, some big and some small. Questions about meaning, purpose, and direction of our life. At times, life is clear and full of joy. At other times, it is uncertain, unpre ...
Here's Why Fujifilm Holdings Corp. (FUJIY) is a Strong Value Stock
ZACKS· 2025-08-25 14:41
Company Overview - FUJIFILM Holdings Corporation is based in Tokyo and utilizes its expertise in photographic film technology to explore opportunities in Healthcare, Electronics, and Imaging markets, with a diversified business model that includes imaging, healthcare, and materials [11] - The company reported revenues of ¥2,960.9 billion for fiscal 2023, reflecting a year-over-year increase of 3.6% [11] Financial Performance - For fiscal 2026, one analyst has revised their earnings estimate upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.01 to $0.73 per share [12] - FUJIFILM has an average earnings surprise of +5.7%, indicating a positive trend in earnings performance [12] Investment Ratings - FUJIFILM is currently rated as 3 (Hold) on the Zacks Rank, with a VGM Score of A, suggesting a solid overall performance [12] - The company also has a Value Style Score of B, supported by attractive valuation metrics such as a forward P/E ratio of 16.9, which may appeal to value investors [12][13]
OSI (OSIS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
ZACKS· 2025-08-21 15:01
Group 1 - OSI Systems reported revenue of $504.99 million for the quarter ended June 2025, reflecting a 5% increase year-over-year and a surprise of +2.34% over the Zacks Consensus Estimate of $493.43 million [1] - The earnings per share (EPS) for the quarter was $3.24, compared to $2.84 in the same quarter last year, resulting in an EPS surprise of +1.57% against the consensus estimate of $3.19 [1] - The stock has returned -1.4% over the past month, while the Zacks S&P 500 composite has changed by +1.7%, with a Zacks Rank 2 (Buy) indicating potential outperformance in the near term [3] Group 2 - Revenue from the Healthcare division was $42.68 million, which is -15.2% lower than the estimated $50.9 million [4] - Intersegment eliminations reported revenue of $-17.34 million, showing a +24.1% change compared to the year-ago quarter [4] - The Optoelectronics and Manufacturing division generated $112.67 million in revenue, exceeding the average estimate of $107.37 million, representing a +10.4% year-over-year change [4] - The Security division reported revenue of $366.97 million, surpassing the average estimate of $349.95 million, with a +7.1% change year-over-year [4] - Non-GAAP operating income for the Security Division was $74.71 million, above the average estimate of $71.57 million [4] - Non-GAAP operating income for the Healthcare Division was $0.37 million, below the average estimate of $4.31 million [4] - Non-GAAP operating income for the Optoelectronics and Manufacturing Division was $15.33 million, slightly above the average estimate of $15.32 million [4]